Helvetia (HELN SW) – FY gross premiums 5.256bn (vs cons 5.202bn) / net profit 423.8m (vs cons 357.6m) Outlook: says combined ratio non-life “well below 100” (BB)

Speedel (SPPN SW) – FY EBIT -85.6m (vs cons -78m) / net loss -91.1m (- 83.3m) Outlook: sees cash burn rate in ’07 at CHF 75-83m – says it can finance operations until end 2008 – company still in discussions with FDA on SPP200 and will announce decision during ’07, no longer in Q1 (BB)

Dätwyler (DAE SW) – FY revenues up 11% to 1.21bn (vs 1.21bn) / EBIT 90m (vs 86m) / net 76.5m (vs 75.6m) Outlook: company proposes split bearer shares 100:1 – cancels 10k unissued shares (BB)

Arpida (ARPN SW) –  Arpida  says AR-709 showed “promising” results in human tests (BB)

Bellevue Group (BBN SW) – FY revenues 101.1m (vs 55.5m y/y) / net 120m (vs 59.7m y/y) / AuM 6.8bn (vs 10.9bn y/y) Outlook: company will increase dividend from CHF 2 to CHF 5 (BB)

SwissLife (SLHN VX) – CS IB increase price target from CHF 338 to CHF 370, reiterate outperform rating (CS IB research update)

Rieter (RIEN SW) – CS IB cut price target from CHF 719 to CHF 650, rating neutral (CS IB research update)

Roche (ROG VX) – Avastin gets EU approval for breast cancer (BB) Accutane (acne treatment) isn’t safe to buy online – internet sales raises risk that patients will have babies with birth defect, US regulators warned (BB)

Syngenta (SYNN VX) – to buy German flower company Fischer Group for $67m (BB)